News Summary Q4 2025 net sales of $961 million increased 6.2% , constant currency sales increased 2.5% Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of tax Q4 2025 adjusted EPS of $0.27 FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50 (1) Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistry Initiated new capital allocation strategy by eliminating the dividend and redeploying capital toward debt retirement and share repurchases Established new agreements with Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec Launched Surity™ Female External Catheter to enter a new market category in the U.S. Appointed three new members to the Board of Directors: James Forbes, former Vice Chairman Investment Bank of Morgan Stanley; Brian McKeon, former CFO of IDEXX Laboratories, Inc.; and Don Zurbay, former CEO of Patterson Dental CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year of 2025.
